An international consortium published work in Nature Communications identifying and engineering key biosynthetic steps that had limited microbial production of the anthracycline doxorubicin for over 50 years. Researchers mapped molecular bottlenecks and modified a production strain to dramatically increase yields, addressing long‑standing scale‑up barriers. Independent reporting confirmed the advance and an accompanying consortium statement highlighted broader implications for manufacturing complex natural‑product therapeutics. The results could lower production costs and expand access to an essential chemotherapy, while also demonstrating the impact of synthetic biology on legacy small‑molecule supply chains.